特里普托利德通过调节巨细胞极化和中性粒细胞活性来缓解由单酸盐晶体引起的急性痛风性关节炎
Yan Du1, Yurong Zhang1, Zhuxin Jiang1
1Faculty of Basic Medicine, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan 650500, China.
Immunology letters
|August 9, 2024
概括
三胺 (TPL) 通过减少炎症和调节免疫细胞活性,有效治疗急性痛风性关节炎 (AGA). 它针对巨细胞两极分化和中性粒细胞功能,为AGA提供了潜在的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 急性痛风性关节炎 (AGA) 是一种痛苦的炎症状况,其特征是单酸盐 (MSU) 水晶沉积.
- 目前对AGA的治疗方法往往存在局限性,需要探索新的治疗药物.
研究的目的:
- 调查三胺 (TPL) 在缓解急性痛风性关节炎 (AGA) 症状方面的疗效.
- 阐明TPL作用的潜在机制,重点关注MSU诱导的AGA模型中的巨细胞极化和中性粒细胞活性.
主要方法:
- 在体内 (老鼠脚模型,气囊实验) 和体内 (巨细胞,中性粒细胞) 进行了研究.
- 这些测试包括ELISA,RT-qPCR,西式斑点测试,免疫组织化学,免疫光和TUNEL测试.
- 分析了炎症的关键标志物,巨细胞两极分化 (M1/M2),PI3K/AKT通路,中性粒细胞功能和亡.
主要成果:
- 在大鼠脚和血清中,TPL显著抑制炎症细胞透和炎症媒介释放.
- 通过PI3K/AKT通路,TPL调节了对抗炎症表型的巨细胞两极分化.
- TPL抑制了中性粒细胞迁移,细胞外陷的形成,并诱导了中性粒细胞的亡.
结论:
- 特里普托利德在预防和治疗MSU诱导的急性痛风性关节炎方面显示出显著的治疗潜力.
- TPL通过PI3K/Akt通路调节巨细胞极化并调节中性粒细胞活性来发挥其作用.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
Antiasthma Drugs: Leukotriene Modifiers
267
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
267
Drugs for Treatment of Ulcerative Colitis in IBD
133
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
133
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
109
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
109
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124


